The agreement builds on a clinical collaboration between the companies pursuant to which amezalpat was combined with ...

Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

This call is being recorded and will be available for the replay on the company's website. I would like to turn the conference over to D'Andre Wright, Vice President of External Affairs and ...

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis ...

Portal vein thrombosis (PVT) is a challenging complication in liver cirrhosis, with no currently available sensitive ...

Why one of Houston Community College’s first students pursuing an artificial intelligence bachelor’s degree, calls the ...

HCC risk prediction may be poorly reported and biased for individuals ... The final models were presented as an equation (n=2), a point-based model (n=2), a nomogram (n=2), and a web-based tool (n=1).

"We look forward to further advancing the anti-GPC3 in vivo CAR-M therapy for HCC patients and continuing our collaboration ... audiobook, ebook and website that reflects on the radical transformation ...

Warrior Met Coal, Inc. (NYSE: HCC) ("Warrior" or the "Company") today announced results for the third quarter of 2024.

Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors The abstract, titled "Pre-Clinical Efficacy of a Novel Anti-GPC3 In Vivo CAR-M for ...

REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2024 and ...